The stock of Kiora Pharmaceuticals Inc (KPRX) has gone up by 26.71% for the week, with a 15.64% rise in the past month and a -6.81% drop in the past quarter. The volatility ratio for the week is 20.34%, and the volatility levels for the past 30 days are 12.32% for KPRX. The simple moving average for the past 20 days is 15.01% for KPRX’s stock, with a 4.19% simple moving average for the past 200 days.
Is It Worth Investing in Kiora Pharmaceuticals Inc (NASDAQ: KPRX) Right Now?
The stock has a 36-month beta value of -0.21. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for KPRX is 2.71M, and at present, short sellers hold a 0.62% of that float. On June 17, 2024, the average trading volume of KPRX was 26.46K shares.
KPRX) stock’s latest price update
Kiora Pharmaceuticals Inc (NASDAQ: KPRX) has experienced a rise in its stock price by 10.74 compared to its previous closing price of 4.84. However, the company has seen a gain of 26.71% in its stock price over the last five trading days. newsfilecorp.com reported 2024-05-20 that Encinitas, California–(Newsfile Corp. – May 20, 2024) – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) (“Kiora” or the “Company”), will participate in two upcoming investor conferences that will be available to investors live with the replay available on-demand. On Wednesday May 22, at 3:00 pm Eastern Time, Kiora’s Executive Vice President of Finance, Melissa Tosca, will participate in the WeBull Corporate Connect Biotech Investment Webinar.
KPRX Trading at 13.65% from the 50-Day Moving Average
After a stumble in the market that brought KPRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.33% of loss for the given period.
Volatility was left at 12.32%, however, over the last 30 days, the volatility rate increased by 20.34%, as shares surge +2.42% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.51% upper at present.
During the last 5 trading sessions, KPRX rose by +26.71%, which changed the moving average for the period of 200-days by +14.53% in comparison to the 20-day moving average, which settled at $4.67. In addition, Kiora Pharmaceuticals Inc saw 14.00% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KPRX starting from Daniels Eric Joseph, who purchase 1,431 shares at the price of $5.29 back on Jun 14 ’24. After this action, Daniels Eric Joseph now owns 11,222 shares of Kiora Pharmaceuticals Inc, valued at $7,570 using the latest closing price.
Tosca Melissa, the EVP Finance of Kiora Pharmaceuticals Inc, purchase 100 shares at $5.25 during a trade that took place back on Jun 14 ’24, which means that Tosca Melissa is holding 3,979 shares at $525 based on the most recent closing price.
Stock Fundamentals for KPRX
Current profitability levels for the company are sitting at:
- 0.16 for the present operating margin
- 0.99 for the gross margin
The net margin for Kiora Pharmaceuticals Inc stands at 0.17. The total capital return value is set at 0.07. Equity return is now at value 12.46, with 9.52 for asset returns.
Based on Kiora Pharmaceuticals Inc (KPRX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at 75.69. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is 72.06.
Currently, EBITDA for the company is -8.63 million with net debt to EBITDA at -3.17. When we switch over and look at the enterprise to sales, we see a ratio of -0.94. The receivables turnover for the company is 8.15for trailing twelve months and the total asset turnover is 0.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 21.02.
Conclusion
To sum up, Kiora Pharmaceuticals Inc (KPRX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
